Status:
SUSPENDED
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
Lead Sponsor:
Shanghai Mental Health Center
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of this study is to evalu...
Eligibility Criteria
Inclusion
- Meets the Diagnostic and Statistical Manual of Mental Disorder,Fifth Edition(DSM-V) criteria for Schizophrenia.
- Patients have got standard treatment of olanzapine monotherapy for more than 6 months, PANSS baseline ≤ 60.
- Meets the ATP-III criteria for metabolic syndrome.
- Male or female subjects aged 18-60 years, education level of junior high school for above.
- The patient fully understand and signed the informed consent form.
Exclusion
- Serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases.
- Pregnant or lactating women and women of childbearing potential throughout the study period; patients who have plans to move to other places within the year.
- History of diabetes, hyperlipidemia and other metabolic abnormalities.
- Due to other reasons, the researchers considered it unsuitable to participate in this clinical trial.
- \-
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04518319
Start Date
October 1 2020
End Date
November 1 2024
Last Update
April 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030